Nasdaq

Exagen Inc. Celebrates Milestone of 1,000,000 AVISE CTD Tests Completed for Autoimmune Diagnostics

Exagen Inc. has reached a major milestone by completing its 1,000,000th AVISE CTD test, a diagnostic tool for autoimmune and connective tissue diseases. This achievement highlights the company’s ...
Seeking Alpha

Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD

CARLSBAD, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (XGN), a leading provider of autoimmune testing, today announced the completion of its 1,000,000 th AVISE CTD test, marking a ...
Lupus Foundation of America

Blood test can help doctors diagnose lupus

What is the AVISE® CTD? AVISE® CTD is a blood test that can help doctors diagnose lupus and other autoimmune diseases — like rheumatoid arthritis, Sjögren's syndrome, or scleroderma. The test may be ...
Nasdaq

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic Lupus ...
manilatimes

Exagen Inc. Announces Select Preliminary 2025 Financial Results

Record full year 2025 revenue, an increase of at least 19% over 2024 AVISE CTD trailing 12-month (TTM) ASP expansion by at least $30 compared to 2024 AVISE CTD test volume growth of at least 13,000, ...